Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (421-430 of 636) with videos related to

Pageof 64
Sort By:
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Circulation. Cardiovascular Interventions|July 13, 2019
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary InterventionChristoph B Olivier, Deepak L Bhatt, Sergio Leonardi, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2020
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID TrialAjar Kochar, Hillary Mulder, Frank W Rockhold, et al.
American Heart Journal|December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trialPierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
Pageof 64

Showing results (421-430 of 636) with videos related to

Sort By:
Pageof 64
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Circulation. Cardiovascular Interventions|July 13, 2019
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary InterventionChristoph B Olivier, Deepak L Bhatt, Sergio Leonardi, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2020
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID TrialAjar Kochar, Hillary Mulder, Frank W Rockhold, et al.
American Heart Journal|December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trialPierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
Pageof 64